Publications by authors named "S Leaw"
Purpose: First-line tislelizumab plus chemotherapy significantly improved progression-free survival (PFS) versus chemotherapy alone in advanced squamous non-small-cell lung cancer (sq-NSCLC) at the interim analysis of the phase III RATIONALE-307 trial. We present the final analysis of this trial.
Patients And Methods: Patients with treatment-naive, stage IIIB/IV, sq-NSCLC were randomized (1 : 1: 1) to 21-day cycles of i.
Article Synopsis
- - This study assessed health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer who were part of the RATIONALE-309 trial, comparing those receiving tislelizumab with chemotherapy to those getting placebo with chemotherapy.
- - A total of 263 patients were randomized, with 43% having liver metastases; the study found no significant differences in HRQoL scores at certain points, though notable pain score improvements were seen in the tislelizumab group by cycle 8.
- - Overall, the results suggest that combining tislelizumab with chemotherapy may be a promising first-line treatment option for this type of cancer due to better survival, improved quality of life,
Article Synopsis
- The phase 3 RATIONALE-312 study tested the combination of tislelizumab and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), which typically has a poor prognosis.
- Conducted in China, the trial involved randomizing 457 untreated ES-SCLC patients to receive either tislelizumab with chemotherapy or a placebo with chemotherapy, with overall survival as the main goal.
- Results showed that the tislelizumab group had a significant survival advantage and improved progression-free survival compared to the placebo group, with both treatments having manageable side effects.
Article Synopsis
- The RATIONALE-307 study shows that using tislelizumab combined with chemotherapy improves progression-free survival (PFS) for patients with advanced lung squamous cell carcinoma compared to chemotherapy alone.
- Researchers found an immune-related gene expression signature that may help identify which patients will benefit most from this treatment, regardless of their PD-L1 levels or tumor mutational burden.
- The study also reveals that activation of the NRF2 pathway can negatively affect PFS by influencing PD-L1 expression, potentially complicating the predictive value of PD-L1 and TMB in treatment outcomes.
Article Synopsis
- - Checkpoint inhibitors like tislelizumab have shown effectiveness in treating recurrent/metastatic nasopharyngeal cancer (R/M NPC), significantly improving progression-free survival (PFS) compared to placebo when combined with chemotherapy.
- - In a clinical trial (RATIONALE-309), patients receiving tislelizumab with chemotherapy had better outcomes regardless of their programmed death-ligand 1 expression, and the overall safety of the treatment was similar to the placebo group.
- - Gene expression profiling identified specific tumor characteristics that were associated with better PFS in patients treated with tislelizumab-chemotherapy, suggesting this combination should be considered for first-line treatment in R/M NPC and could help select the best candidates for therapy